We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Unraveling Molecular Links Between Chronic Kidney Disease and Heart Failure via the Plasma Proteome

MedXY Editorial Team•Oct 3, 2025•Cardiology
biomarkerschronic kidney diseaseheart failure

Background and Disease Burden

Chronic kidney disease (CKD) is a prevalent condition globally, affecting millions and substantially increasing the risk of cardiovascular complications, notably heart failure (HF). HF presents a major clinical burden with high morbidity and mortality rates. Understanding the pathogenic links between CKD and incident HF remains a critical unmet need. Circulating plasma proteins, as functional effectors and biomarkers, offer a window into molecular pathways that may contribute to HF development in CKD populations. Advanced proteomic technologies now enable comprehensive screening of plasma proteins to uncover novel mechanistic insights and potential clinical targets.

Study Design

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Unlocking the Potential of Novel Biomarkers for Acute Kidney Injury in the Critically Ill: A Comprehensive Evidence MappingThis article reviews over 1100 studies on novel biomarkers for acute kidney injury (AKI) in critically ill patients, highlighting their predictive, diagnostic, and management roles while identifying gaps for future clinical implementation.Sep 18, 2026KDIGO 2026 on Anemia in CKD: Key Recommendations and Practical Guidance for CliniciansKDIGO 2026 updates anemia care in CKD: evidence-based thresholds for iron therapy, preference for IV iron on hemodialysis, ESA-first approach over HIF-PHIs, individualized Hb initiation, and an ESA maintenance upper Hb target <11.5 g/dL.Sep 18, 2026Blood Transcriptomic Signatures as Predictors of Poor Outcomes in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Brazilian CohortHost blood transcriptomic signatures effectively monitor treatment response and predict recurrence and mortality in drug-susceptible pulmonary tuberculosis, meeting WHO benchmarks and enabling personalized therapy strategies.Sep 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Bridging Evidence-Based and Personalized Medicine in Heart Failure and Cardiomyopathies: Balancing Standardization with Individualization
This article explores the integration of evidence-based medicine and personalized approaches in managing heart failure and inherited cardiomyopathies, proposing a framework to optimize patient care by harmonizing standardized guidelines wit
Sep 17, 2026
Cardiac Resynchronization Therapy: Metabolomic Insights into Heart Failure ImprovementThis study reveals how cardiac resynchronization therapy (CRT) improves left ventricular function in heart failure patients and modulates systemic metabolomic profiles, highlighting differences between ischemic and nonischemic cardiomyopathSep 15, 2026
Heart Failure in Portuguese Adults Aged 50 and Above: Insights from the PORTHOS Study on Prevalence and Predominant PhenotypesThe PORTHOS study reveals a 16.5% prevalence of heart failure among Portuguese adults aged 50+, with HFpEF constituting over 90% of cases, mostly undiagnosed, highlighting the need for enhanced screening strategies in aging populations.Sep 15, 2026